Opinion

Video

Potential Impact of PET/CT Imaging on Improving Patient Care

Author(s):

Neal Shore, MD, FACS,Brian M. Shuch, MD

Neal Shore, MD, FACS, and Brian Shuch, MD, provide closing thoughts on the potential of PET/CT imaging to improve patient care in kidney cancer.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Related Videos
      Darren Feldman, MD, on study of 177Lu-girentuximab plus nivolumab for ccRCC
      Darren Feldman, MD, on study of 177Lu-girentuximab plus nivolumab for ccRCC
      Francesca Jackson-Spence, MBChB, details the ongoing SAMETA trial in papillary renal cancer
      Francesca Jackson-Spence, MBChB, details the ongoing SAMETA trial in papillary renal cancer
      Kate Gessner, MD, on systemic agents vs MDT after kidney cancer progression
      Kate Gessner, MD, on systemic agents vs MDT after kidney cancer progression
      Taylor Goodstein, MD, highlights project on staging in larger kidney tumors
      Taylor Goodstein, MD, highlights project on staging in larger kidney tumors
      Chad Tang, MD: Considerations for SBRT in metastatic RCC
      Chad Tang, MD: Considerations for SBRT in metastatic RCC
      Considering patient-reported outcomes in kidney cancer care, with Nicholas Zaorsky, MD, PhD
      Considering patient-reported outcomes in kidney cancer care, with Nicholas Zaorsky, MD, PhD
      Nicholas Zaorsky, MD, MS: Protecting kidney function after local renal cell carcinoma therapy
      Nicholas Zaorsky, MD, MS: Protecting kidney function after local renal cell carcinoma therapy
      Dr. Toni Choueiri on key takeaways from TiNivo-2 trial
      Dr. Toni Choueiri on key takeaways from TiNivo-2 trial
      ESMO 2024: Dr. Jonasch on implications of positive HIF-2α inhibitor data in ccRCC
      ESMO 2024: Dr. Jonasch on implications of positive HIF-2α inhibitor data in ccRCC
      Human kidney cross section on scientific background | © Crystal light - stock.adobe.com
      Expert discusses pooled analysis of cytoreductive nephrectomy
      Related Content
      Sintilimab/fruquintinib combo meets primary PFS end point in advanced RCC
      March 19th 2025

      Sintilimab/fruquintinib combo meets primary PFS end point in advanced RCC

      Hannah Clarke
      "The positive results from this phase 3 study of the sintilimab and fruquintinib combination represent a significant advancement in the treatment of advanced renal cell carcinoma,” says Prof Zhisong He.
      FDA greenlights trial of orellanine in metastatic renal cell carcinoma
      March 18th 2025

      FDA greenlights trial of orellanine in metastatic renal cell carcinoma

      Hannah Clarke
      The study will evaluate the investigational drug product ONC175 (orellanine) in patients with metastatic clear cell or papillary renal cell carcinoma.
      Identifying unique therapeutic targets for chromophobe kidney cancer
      March 6th 2025

      Identifying unique therapeutic targets for chromophobe kidney cancer

      David A. Braun, MD, PhD Hannah Clarke
      “What we hope overall is that this is a biological study that might inform therapeutic development for this disease,” says David A. Braun, MD, PhD.
      FDA updates in urology: February 2025
      March 3rd 2025

      FDA updates in urology: February 2025

      Hannah Clarke
      A recap of the FDA submissions and regulatory decisions in urology from February 2025.
      Camillo Porta, MD, offers key takeaways from CheckMate 9ER trial in renal cell carcinoma
      February 26th 2025

      Camillo Porta, MD, offers key takeaways from CheckMate 9ER trial in renal cell carcinoma

      Camillo Porta, MD
      "At ASCO GU, we presented the final analysis of the study, which confirmed the superiority of a combination over the TKI monotherapy in terms of both progression-free survival as well as overall survival," says Camillo Porta, MD.
      Human kidney cross section on science background. 3d render. | Image Credit: © Rasi - stock.adobe.com
      February 20th 2025

      Final CheckMate 9ER data show long-term efficacy of nivolumab/cabozantinib in RCC

      Benjamin P. Saylor
      Robert J. Motzer, MD, reported that median PFS was 16.4 months in the nivolumab plus cabozantinib arm (95% CI, 12.5-19.3) vs 8.3 months in the sunitinib arm (95% CI, 7.0-9.7) (HR=0.58, 95% CI, 0.49-0.70).
      © 2025 MJH Life Sciences

      All rights reserved.